Abstract
Platelet activation is a critical mechanism in acute coronary artery syndromes and ischemic complications of percutaneous coronary revascularization. Thrombin and platelet inhibition are the current mainstays of therapy for these problems. Inhibitors of platelet GP IIb-IIIa, the final common pathway of platelet aggregation, have recently undergone clinical evaluation as therapeutics for acute ischemic syndromes, and as adjuvants for percutaneous revascularization. The results of these prospective, controlled trials, and current evaluations of GP IIb-IIIa inhibitors are summarized in this review.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
